相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models
James P. B. O'Connor et al.
CANCER RESEARCH (2016)
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Roger M. Phillips
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia
Donya Moradi Manesh et al.
BLOOD (2015)
Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole
N. C. Dhani et al.
BRITISH JOURNAL OF CANCER (2015)
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs
Francis W. Hunter et al.
CANCER RESEARCH (2015)
Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment
Susan E. Scanlon et al.
DNA REPAIR (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: A systematic review and meta-analysis
Yang Gao et al.
ORAL ONCOLOGY (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
James P. B. O'Connor et al.
CLINICAL CANCER RESEARCH (2015)
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5
Jingli Wang et al.
BIOCHEMICAL PHARMACOLOGY (2014)
The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs
Francis W. Hunter et al.
BIOCHEMICAL PHARMACOLOGY (2014)
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells
Stephen M. F. Jamieson et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?
Nikola A. Bowden
CANCER LETTERS (2014)
Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer
Mateya E. Trinkaus et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2014)
Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer
Francis W. Hunter et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
Emilie Lalonde et al.
LANCET ONCOLOGY (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
The human flavoproteome
Wolf-Dieter Lienhart et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2013)
Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: Comparison with other hypoxia-activated prodrugs
Francis W. Hunter et al.
BIOCHEMICAL PHARMACOLOGY (2012)
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
Mark J. McKeage et al.
BMC CANCER (2012)
Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Jessica D. Sun et al.
CLINICAL CANCER RESEARCH (2012)
The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia
Jingli Wang et al.
CLINICAL CANCER RESEARCH (2012)
Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer
Michael Milosevic et al.
CLINICAL CANCER RESEARCH (2012)
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Fanying Meng et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck
Kasper Toustrup et al.
RADIOTHERAPY AND ONCOLOGY (2012)
Hypoxia Gene Expression Signatures as Prognostic and Predictive Markers in Head and Neck Radiotherapy
Kasper Toustrup et al.
SEMINARS IN RADIATION ONCOLOGY (2012)
Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia
Christopher P. Guise et al.
MOLECULAR PHARMACOLOGY (2012)
Development of a Hypoxia Gene Expression Classifier with Predictive Impact for Hypoxic Modification of Radiotherapy in Head and Neck Cancer
Kasper Toustrup et al.
CANCER RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Initial Testing of the Hypoxia-Activated Prodrug PR-104 by the Pediatric Preclinical Testing Program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2011)
Targeting hypoxia in cancer therapy
William R. Wilson et al.
NATURE REVIEWS CANCER (2011)
The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3
Christopher P. Guise et al.
CANCER RESEARCH (2010)
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Norman Chan et al.
CANCER RESEARCH (2010)
Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors
Kevin O. Hicks et al.
CLINICAL CANCER RESEARCH (2010)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer
Pernille Lassen et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A
Yongchuan Gu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis
Lane Birtwistle et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2009)
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance
Norman Chan et al.
CANCER RESEARCH (2008)
Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells
James W. Evans et al.
CANCER RESEARCH (2008)
Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-diniti-obenzamide (CB1954) by NO synthases
Alexia Chandor et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Bradly G. Wouters et al.
NATURE REVIEWS CANCER (2008)
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: Comparison of the dinitrobenzamide mustard PR-104A and tirapazamine
Kevin O. Hicks et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A:: A role for NADPH:cytochrome P450 oxidoreductase under hypoxia
Chris P. Guise et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104
Adam V. Patterson et al.
CLINICAL CANCER RESEARCH (2007)
Bystander effects of bioreductive drugs: Potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards
William R. Wilson et al.
RADIATION RESEARCH (2007)
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine:: A substudy of Trans-Tasman Radiation Oncology Group study 98.02
D Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study
M Nordsmark et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia
P Wardman
CURRENT MEDICINAL CHEMISTRY (2001)
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer
D Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Pancreatic tumors show high levels of hypoxia
AC Koong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
分享论文
